External Link

You are now leaving the Grünenthal website. You will be re-directed to an external website. Grünenthal accepts no responsibility for the content of other websites.

Media Statements

2022/2020

February 25, 2026
World Health Organisation proposes International Non-proprietary Name ‘tegacorat’ for Grünenthal’s investigational medicine GRM-01
In their INN Proposed List 133 (Page 258), the World Health Organisation (WHO) proposed the International Non-proprietary Name (INN) ‘tegacorat’ for our investigational medicine GRM-01, a non-steroidal selective glucocorticoid receptor agonist and modulator (SEGRAM). We anticipate the inclusion in the INN Recommended List in March 2026.
View more
December 20, 2022
Preliminary injunction obtained against marketing of generic versions of Palexia^® retard in Germany
On 20 December 2022, the Düsseldorf Regional Court (Landgericht Düsseldorf) granted a preliminary injunction in favor of Grünenthal against two generic companies for commercialization of generic versions of Palexia® retard in Germany. The generic companies are 1A Pharma and Ratiopharm.
View more
May 5, 2022
Return to market following recall of Palexia^® 20mg/ml oral solution and Palexia^® 4 mg/ml oral solution
In February 2021, Grünenthal initiated a voluntary recall of all batches of Palexia® 20 mg/ml oral solution and Palexia^® 4 mg/ml oral solution due to a bacterial contamination in some batches. We have now received full approval to reintroduce these products back to the market.
View more
February 7, 2022
Grünenthal’s response to Covid-19
Grünenthal considers the outbreak and spread of Covid-19 to be a serious situation and fully recognises its responsibilities related to safeguarding the well-being and safety of our employees. We work to ensure an uninterrupted supply of our medicines for patients and supporting communities with curbing the Covid-19 outbreak.
View more
November 27, 2021
60 Years after the market withdrawal: Dr. Michael Wirtz apologises to those affected on behalf of his family
On the occasion of 60 years after the market withdrawal of Thalidomide, Dr. Michael Wirtz, shareholder of Grünenthal, apologised to those affected and their families on behalf of his family. As company, we welcome this step.
View more
February 16, 2021
Initial results from Mesoblast’s Phase III trial MSB-DR003
In 2019, Grünenthal entered into a partnership with Mesoblast, a world leader in cellular medicines, to develop the investigational medicine MPC-06-ID, an innovative cell therapy for patients who suffer from chronic low back pain associated with degenerative disc disease, and who have exhausted conservative treatment options.
View more
February 1, 2021
Statement on the recall of two batches of Anulette in Chile
As a science-driven company, it is our commitment to provide safe and effective oral contraceptives so that women are in a position to make their own decision and choices about their reproductive health.
View more
October 19, 2020
Grünenthal terminates license supply agreement for ZALVISO™
Grünenthal has issued notice to AcelRx Pharmaceuticals, Inc. to terminate the supply license agreement for Zalviso™.
View more
June 30, 2020
Grünenthal issues notice to the European Commission (EC) and the European Medicines Agency (EMA) to withdraw Zurampic^® and Duzallo^®
Grünenthal issued notice to the European Commission (EC) and the European Medicines Agency (EMA) to withdraw Zurampic® (lesinurad)¹ and Duzallo^® (lesinurad and allopurinol, currently not marketed)² for the treatment of chronic hyperuricaemia in adults with gout, who have not achieved target serum uric acid levels with an adequate dose of a Xanthine Oxidase Inhibitor (XOI) alone, from the market in Europe. Zurampic and Duzallo will not be marketed in Latin America.
View more
June 24, 2020
German federal parliament strengthens legal certainty for Thalidomide-affected people
The German federal parliament adopted an amendment to the Contergan Foundation Act on 19 June 2020, whereby benefits to Thalidomide victims, once granted, cannot be revoked. This includes the Thalidomide pension, which is paid by the Contergan Foundation. Only in special cases, such as deliberate deception, is it possible to withdraw benefits.
View more

Matt Crabb, Head of Global Communications (Interim)

Matt Crabb
Head of Global Communications (Interim)

Grünenthal GmbH
52099 Aachen

+44 7813 210392
matt.crabb@grunenthal.com

Media Statements | Grünenthal